Evidence map›Paper›PMID 33685501›Full record

Observational studyJournal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance2021

Cardiovascular magnetic resonance predictors of heart failure in hypertrophic cardiomyopathy: the role of myocardial replacement fibrosis and the microcirculation.

Claire E Raphael, Frances Mitchell, Gajen Sunthar Kanaganayagam, Alphonsus C Liew, Elisa Di Pietro, Miguel Silva Vieira, Lina Kanapeckaite, Simon Newsome, John Gregson, Ruth Owen and 15 more

Open access · goldAbstract readObservational Study
In one paragraph

Observational study in Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
2.7field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 29 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Cardiac Magnetic Resonance in Heart Failure: Diagnostic and Prognostic Assessments.Journal of cardiovascular development and disease · 2025
    Review
  10. Cardiac Phase-Resolved TBiomedicines · 2025
    Article
  11. Article
  12. Article
  13. Review
  14. Mechanisms and prognostic impact of myocardial ischaemia in hypertrophic cardiomyopathy.The international journal of cardiovascular imaging · 2023
    Review
  15. Article
  16. 2021-2022 state of our JCMR.Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance · 2022
    Review
  17. Review
  18. Review
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors at 6 institutions in 4 countries.

Claire E RaphaelNIHR Cardiovascular Biomedical Research Unit, Royal Brompton Hospital, London, UK. claire.raphael@gmail.com.ORCID 0000-0002-2206-0413
Frances MitchellNIHR Cardiovascular Biomedical Research Unit, Royal Brompton Hospital, London, UK.
Gajen Sunthar KanaganayagamNIHR Cardiovascular Biomedical Research Unit, Royal Brompton Hospital, London, UK.
Alphonsus C LiewNIHR Cardiovascular Biomedical Research Unit, Royal Brompton Hospital, London, UK.
Elisa Di PietroDepartment of Advanced Biomedical Sciences, University of Naples, Naples, Italy.
Miguel Silva VieiraNIHR Cardiovascular Biomedical Research Unit, Royal Brompton Hospital, London, UK.
Lina KanapeckaiteNIHR Cardiovascular Biomedical Research Unit, Royal Brompton Hospital, London, UK.
Simon NewsomeLondon School of Hygiene & Tropical Medicine, London, UK.
John GregsonLondon School of Hygiene & Tropical Medicine, London, UK.
Ruth OwenLondon School of Hygiene & Tropical Medicine, London, UK.
Li-Yueh HsuAdvanced Cardiovascular Imaging Laboratory, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, USA.
Vassilis VassiliouNIHR Cardiovascular Biomedical Research Unit, Royal Brompton Hospital, London, UK.
Robert CooperNIHR Cardiovascular Biomedical Research Unit, Royal Brompton Hospital, London, UK.
Aamir Ali MrcpNIHR Cardiovascular Biomedical Research Unit, Royal Brompton Hospital, London, UK.
Tevfik F IsmailKing's College London & Guy's and St Thomas' NHS Foundation Trust, London, UK.
Brandon WongNIHR Cardiovascular Biomedical Research Unit, Royal Brompton Hospital, London, UK.
Kristi SunNIHR Cardiovascular Biomedical Research Unit, Royal Brompton Hospital, London, UK.
Peter GatehouseNIHR Cardiovascular Biomedical Research Unit, Royal Brompton Hospital, London, UK.
David FirminNIHR Cardiovascular Biomedical Research Unit, Royal Brompton Hospital, London, UK.
Stuart CookNIHR Cardiovascular Biomedical Research Unit, Royal Brompton Hospital, London, UK.
Michael FrenneauxNorwich Medical School, University of East Anglia, Norwich, UK.
Andrew AraiAdvanced Cardiovascular Imaging Laboratory, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, USA.
Rory O'HanlonBlackrock Clinic, Co. Dublin, Ireland.
Dudley J PennellNIHR Cardiovascular Biomedical Research Unit, Royal Brompton Hospital, London, UK.
Sanjay K PrasadNIHR Cardiovascular Biomedical Research Unit, Royal Brompton Hospital, London, UK.
Royal Brompton Hospital · GBLondon School of Hygiene & Tropical Medicine · GBNational Institutes of Health · USUniversity of East Anglia · GBKing's College London · GBUniversity of Naples Federico II · IT

Funding

British Heart Foundation FS/14/13/30619Medical Research Council MC_U120085815Wellcome Trust
6 · The paper itself

Abstract

introductionHeart failure (HF) in hypertrophic cardiomyopathy (HCM) is associated with high morbidity and mortality. Predictors of HF, in particular the role of myocardial fibrosis and microvascular ischemia remain unclear. We assessed the predictive value of cardiovascular magnetic resonance (CMR) for development of HF in HCM in an observational cohort study.

methodsSerial patients with HCM underwent CMR, including adenosine first-pass perfusion, left atrial (LA) and left ventricular (LV) volumes indexed to body surface area (i) and late gadolinium enhancement (%LGE- as a % of total myocardial mass). We used a composite endpoint of HF death, cardiac transplantation, and progression to NYHA class III/IV.

resultsA total of 543 patients with HCM underwent CMR, of whom 94 met the composite endpoint at baseline. The remaining 449 patients were followed for a median of 5.6 years. Thirty nine patients (8.7%) reached the composite endpoint of HF death (n = 7), cardiac transplantation (n = 2) and progression to NYHA class III/IV (n = 20). The annual incidence of HF was 2.0 per 100 person-years, 95% CI (1.6-2.6). Age, previous non-sustained ventricular tachycardia, LV end-systolic volume indexed to body surface area (LVESVI), LA volume index ; LV ejection fraction, %LGE and presence of mitral regurgitation were significant univariable predictors of HF, with LVESVI (Hazard ratio (HR) 1.44, 95% confidence interval (95% CI) 1.16-1.78, p = 0.001), %LGE per 10% (HR 1.44, 95%CI 1.14-1.82, p = 0.002) age (HR 1.37, 95% CI 1.06-1.77, p = 0.02) and mitral regurgitation (HR 2.6, p = 0.02) remaining independently predictive on multivariable analysis. The presence or extent of inducible perfusion defect assessed using a visual score did not predict outcome (p = 0.16, p = 0.27 respectively). DISCUSSION: The annual incidence of HF in a contemporary ambulatory HCM population undergoing CMR is low. Myocardial fibrosis and LVESVI are strongly predictive of future HF, however CMR visual assessment of myocardial perfusion was not.

Indexed as

Coronary CirculationMagnetic Resonance ImagingMicrocirculationMyocardial Perfusion ImagingAdultAgedCardiomyopathy, HypertrophicDisease ProgressionFemaleFibrosisHeart FailureHumansMaleMiddle AgedMyocardiumPredictive Value of TestsCardiovascular magnetic resonanceFibrosisHeart failureHypertrophic cardiomyopathyMicrovascular ischemiaMyocardial perfusionPrognosis

Identifiers

PMID33685501
PMCPMC7941878
OpenAlexW3135413836

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.